This site is intended for healthcare professionals

FDA approves Lumakras the first and only targeted treatment for KRAS G12C-mutated locally advanced or metastatic NSCLC.-Amgen

Read time: 1 mins
Last updated:28th Jun 2021
Published:29th May 2021
Amgen has announced that the FDA has approved Lumakras (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Condition: NSCLC/KRAS G12C
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest